Shares of Anthem BioSciences Ltd were in focus on Friday, Nov 28, trading 2.79% higher at ₹644.55, after global brokerage Nomura initiated coverage with a ‘Buy’ rating and set a target price of ₹740 per share. The target implies a potential upside of nearly 18% from Thursday’s closing levels.
Nomura said Anthem BioSciences is well positioned to capitalise on the CRDMO (Contract Research, Development and Manufacturing Organisation) opportunity, supported by strong demand trends, an expanding portfolio and new capacity additions. The brokerage expects the company’s sales to grow 14%, 18% and 22% over FY26F–FY28F, while earnings are projected to increase 27%, 21% and 26% during the same period.
The note added that while revenue growth may moderate in the near term due to a high base, momentum is expected to accelerate in FY27F and FY28F, driven by steady demand in base products, fresh launches and additional manufacturing capacity.
Founded in 2006, Anthem BioSciences operates as a full-service CRDMO, providing end-to-end solutions for pharma and biotech companies—spanning early-stage research to commercial manufacturing through an integrated model that aims to simplify processes and reduce compliance complexity.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
